Literature DB >> 16161040

Androgen receptor polymorphisms and endometrial cancer risk.

Monica McGrath1, I-Min Lee, Susan E Hankinson, Peter Kraft, David J Hunter, Julie Buring, Immaculata De Vivo.   

Abstract

The androgen receptor (AR) gene is a transcription factor responsible for mediating the physiological effects of androgens. Evidence suggests that androgens and the androgen receptor are involved in uterine cell proliferation. A polymorphic CAG repeat in exon 1 of the AR gene encodes a polyglutamine tract that is inversely correlated with the transcriptional activity of this gene. We assessed the association between the functional CAG repeat polymorphism and AR haplotypes and the risk of endometrial cancer in two nested case-control studies within the Nurses' Health Study (n = 222 cases, 666 controls) and the Women's Health Study (n = 137 cases, 411 controls) using conditional and unconditional logistic regression. Associations between AR CAG repeat polymorphism and endometrial cancer risk were similar in the 2 case-control studies. In the pooled analysis, women with an average repeat allele > or =22 repeats compared to <22 repeats were at a statistically significant decreased risk of endometrial cancer (odds ratio (OR) = 0.76; 95% confidence interval (CI), 0.59-0.98). Women with one or two long alleles (> or =27 repeats) compared to both alleles <22 repeats were also at a statistically significant decreased risk (OR = 0.60; 95% CI, 0.36-0.99). We observed a modest yet statistically significant association for each one unit increase in the average repeat length and endometrial cancer risk (OR = 0.94; 95% CI, 0.88-1.00). Associations for the AR CAG average repeat length and endometrial cancer risk differed by menopausal status (p = 0.02). No significant associations between the AR haplotypes and endometrial cancer risk were observed. Our findings suggest that an increasing number of functional CAG repeats may be associated with endometrial carcinogenesis because of AR's reduced ability to recruit coregulators and other transcriptional components. (supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html). (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16161040     DOI: 10.1002/ijc.21436

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  Role of nuclear receptors in blastocyst implantation.

Authors:  Y M Vasquez; F J DeMayo
Journal:  Semin Cell Dev Biol       Date:  2013-08-28       Impact factor: 7.727

2.  Do Genetic Alterations in Sex Steroid Receptors Contribute to Lacrimal Gland Disease in Sjögren's Syndrome?

Authors:  Stephen M Richards; David A Sullivan
Journal:  Open Endocrinol J       Date:  2009

3.  Genetic variation in CYP11A1 and StAR in relation to endometrial cancer risk.

Authors:  Kathryn Terry; Monica McGrath; I-Min Lee; Julie Buring; Immaculata De Vivo
Journal:  Gynecol Oncol       Date:  2010-03-02       Impact factor: 5.482

4.  Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes.

Authors:  Hannah P Yang; Jesus Gonzalez Bosquet; Qizhai Li; Elizabeth A Platz; Louise A Brinton; Mark E Sherman; James V Lacey; Mia M Gaudet; Laurie A Burdette; Jonine D Figueroa; Julia G Ciampa; Jolanta Lissowska; Beata Peplonska; Stephen J Chanock; Montserrat Garcia-Closas
Journal:  Carcinogenesis       Date:  2010-01-06       Impact factor: 4.944

5.  Subfertile female androgen receptor knockout mice exhibit defects in neuroendocrine signaling, intraovarian function, and uterine development but not uterine function.

Authors:  K A Walters; K J McTavish; M G Seneviratne; M Jimenez; A C McMahon; C M Allan; L A Salamonsen; D J Handelsman
Journal:  Endocrinology       Date:  2009-04-09       Impact factor: 4.736

Review 6.  Genetic polymorphisms and endometrial cancer risk.

Authors:  Larissa A Meyer; Shannon N Westin; Karen H Lu; Michael R Milam
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

7.  MDM2 SNP309 is associated with endometrial cancer risk.

Authors:  Kathryn Terry; Monica McGrath; I-Min Lee; Julie Buring; Immaculata De Vivo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

8.  Genetic variation in the androgen receptor gene and endometrial cancer risk.

Authors:  Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Louise A Brinton; Jolanta Lissowska; Beta Peplonska; Stephen Chanock; Mia M Gaudet
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

9.  Meta-analysis of haplotype-association studies: comparison of methods and empirical evaluation of the literature.

Authors:  Pantelis G Bagos
Journal:  BMC Genet       Date:  2011-01-19       Impact factor: 2.797

10.  A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Lori B Chibnik; Monica McGrath; Shun-Chiao Chang; Brendan T Keenan; Karen H Costenbader; Patricia A Fraser; Shelley Tworoger; Susan E Hankinson; I-Min Lee; Julie Buring; Immaculata De Vivo
Journal:  Arthritis Res Ther       Date:  2009-06-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.